A Type C FDA meeting led to a Type D meeting, which now requires a "complete (full) response." Mozz, given these safety concerns, would you kindly share how you know this is not a partial or full clinical hold? (i.e., who provided the information?) Thanks, Mate.
A Type C FDA meeting led to a Type D meeting, which now requires...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.010(4.08%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 26.0¢ | 24.5¢ | $65.17K | 254.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 64000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 14407 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |